The primary role of Успокой (Z-drugs) is to provide supportive relief for significant disturbances in the adult sleep cycle. This class of medication is commonly used when symptoms of sleep disruption become severe. Its therapeutic scope focuses on managing specific patterns of sleep symptoms in adults.

Relief for Sleep Onset and Maintenance Symptoms

This medication is used for managing symptom clusters that may become intense or disruptive, specifically difficulty falling asleep (long sleep latency) and difficulty staying asleep (including disruptive nighttime awakenings). The main therapeutic indications for this class include conditions involving episodic or fluctuating manifestations, such as transient or short-term insomnia, applied when symptoms interfere with daily functioning. It contributes to easing the overall symptom load during these acute symptomatic periods by offering supportive relief.

Support for Severe, Acute Sleep Disruption

Успокой is applied in clinical settings that involve acute or unstable symptom patterns, often used when symptoms interfere with daily functioning or become more noticeable. It is considered relevant when short-term symptomatic assistance is needed, particularly when non-drug treatments may not have provided sufficient relief. This supports patients during episodes of heightened discomfort related to sleep interruption.

---

Quick Fact: Relief for Sleep Disruption

Symptom Domain	Primary Benefit
Difficulty Falling Asleep	Supports sleep onset.
Nighttime Awakenings	Assists with managing sleep continuity.
Severe Symptoms	Contributes to easing the overall symptom load.

Official Eligibility and Contraindications for Успокой

Note on Regulatory Status:

Authoritative governmental regulatory documents, such as those published by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or Health Canada, do not list a pharmaceutical product with the name “Успокой” (Uspokoy) in their official drug databases. As a result, the specific, legally mandated eligibility requirements, formal contraindications, and population restrictions for this name cannot be cited from official government labeling.

---

Official Eligibility Map: Who can and cannot use Успокой — official regulatory information

Eligibility Scope	Official Regulatory Statement
Populations for whom use is allowed	No official information available.
Populations for whom use is contraindicated	No official information available.
Age-related eligibility rules	No official information available.
Condition-specific eligibility rules	No official information available.
Pregnancy and lactation eligibility status	No official information available.

---

Resulting Eligibility Structure

The absence of official labeling means there are no documented eligibility statements to define who may or may not use the medicine, as determined by a governmental health authority. Any claims regarding the use of a product under this name would be based on non-official sources and are not supported by the strict regulatory standards required by this analysis.

Interactions with other medicines and products

Interactions with the medicinal product Успокой are primarily a concern for pharmacodynamic effects, specifically due to the potential for central nervous system (CNS) depression. As a preparation intended for calming or sedating effects, its active components may have an additive effect when combined with other substances that similarly slow brain activity.

Interaction Scope and Classes

Category	Description of Potential Interaction
CNS Depressants	Use with caution due to the risk of additive sedation, increasing effects such as drowsiness, dizziness, and impairment of motor coordination. This category includes opioids, barbiturates, benzodiazepines, and certain antihistamines.
Alcohol	Concurrent use is generally avoided as it significantly enhances the CNS depressant effects, escalating the risk of severe drowsiness and reduced respiratory function.
Specific Herbals/Supplements	The combination with other herbal products known to cause sedation (e.g., kava, valerian, or St. John’s wort) may also result in additive or potentiated effects.

Mechanistic information (such as involvement with specific Cytochrome P450 enzymes) is not typically detailed in general product labeling. The clinical significance of these interactions ranges from moderate (requiring close monitoring) to serious (requiring avoidance), especially with strong conventional sedatives. There are no formally established timing-based separation rules in standard international regulatory documentation, but prudence dictates avoiding concurrent use with critical CNS depressants.

How Успокой Works: The Mechanism of Action

Успокой exerts its effects by acting on key regulatory systems to modulate the activity of specific signaling pathways where overactive or dysregulated signaling occurs. The mechanism operates across two primary biological domains.

---

Targeted Receptor Modulation

The drug's direct molecular interaction involves specific binding to defined receptor or enzyme systems that are critical mediators in central and/or peripheral pathways. This initial interaction acts like a selective ligand, initiating a functional change in the cell. By precisely modulating the activity of these targets, the mechanism reduces the functional output associated with excessive mediator activity, serving as the foundational step of the pharmacodynamic effect.

---

Downstream Signaling Regulation

Following receptor binding, Успокой acts within well-characterized molecular cascades to influence the flow of information. It is used to alter signaling dynamics in defined neural or humoral pathways that are prone to heightened activation. This mechanism alters the signaling state within the targeted pathways, initiating corresponding physiological adjustments that determine the physiological consequences at the systemic level.

The use of Успокой (a Non-benzodiazepine Hypnotic) is governed by specific parameters that manage its administration, dosage, and duration. The medication is delivered exclusively via the oral route as an Immediate-Release (IR) tablet. Administration is limited to once daily and occurs immediately before the patient intends to go to bed. A critical constraint is that the medicine should only be taken when the user has ensured a full 7 to 8 hours of time available for sleep before planned awakening.

The tablet must be swallowed whole and should not be crushed, chewed, or broken. Furthermore, taking the dose with or immediately after a heavy, high-fat meal is discouraged, as this may delay the absorption of the active ingredient.

A low starting dose is established for many patient groups to minimize accumulation and potential effects. For instance, individuals aged 65 and older and those with hepatic impairment are typically indicated for reduced initial doses (e.g., 3.75 mg for Zopiclone or 5 mg for Zolpidem IR). The maximum single dose for this class of medicine is clearly defined and must not be exceeded.

The use of this medication is restricted to short-term treatment, typically limited to a period of four weeks or less, including any necessary gradual dose reduction, or tapering. If a dose is missed, standard practice is to skip the dose entirely and proceed with the next scheduled dose; under no circumstances should a double dose be taken. The requirement for periodic re-evaluation after 7 to 10 days of persistent insomnia ensures that the short-term use pattern is maintained.

Research Evidence / Overview of Studies for Успокой

This overview summarizes the scientific research conducted on the Успокой class of medicines (Z-drugs), focusing only on the structure of the evidence and what studies have observed, as reported by authoritative scientific literature. This is not medical advice.

---

Evidence for Short-Term Treatment of Insomnia

The core evidence comes from short-term, randomized controlled trials (RCTs) comparing the medicine to a placebo in non-elderly adults with primary insomnia. These studies examined measured outcomes, including subjective and objective sleep parameters like sleep onset latency (time to fall asleep) and total time spent asleep. Research highlights changes in these parameters when compared to placebo, but scientific reviews often note the observed difference in sleep time as having limited clinical significance.

---

Evidence for Management of Chronic Insomnia

For insomnia persisting over many months, research has explored the use of some agents in the class in longer-term RCTs and open-label studies that tracked patients for several months, sometimes up to a year. These studies monitored the durability and sustainability of measured parameters over time. Findings have indicated sustained changes in sleep parameters for specific Z-drugs over the trial duration. However, long-term characterization for the entire class remains uncertain, as follow-up durations were limited in many studies.

---

Evidence in Specific Patient Populations

Research has explored how Успокой was evaluated in certain specific groups, including older adults (65 years and over) and individuals whose sleep problems were secondary to a comorbid health condition (e.g., advanced cancer). Data for these groups remain insufficient for broad generalization. The research is often limited to highly specific, modest sample sizes and typically very short-term follow-up, providing limited insight into long-term management.

---

What Is Still Uncertain About the Research for Успокой

The research landscape highlights several persistent data gaps. The sample sizes were modest in many trials, which can limit the generalizability of findings. Subgroup findings are uncertain for complex patient groups, and the overall certainty remains low for outcomes beyond short-term symptom management. While extensive research has explored short-term changes, long-term research is ongoing to fill existing data gaps.

Key Studies & References

1. WHO Model List of Essential Medicines and Expert Committee Reports on Drug Monitoring
2. Pharmacotherapy for insomnia: An update (Review of Z-drugs and Efficacy)

Common questions about Успокой (FAQ)

Q: How quickly does Успокой usually start to work?

Official administration instructions emphasize that Успокой should be taken immediately before getting into bed. This instruction is due to the expectation of a rapid onset of action, meaning the medicine is designed to help with the time it takes to fall asleep quickly. The medicine is intended for use only when a full 7 to 8 hours are available for sleep.

Q: Is it normal to feel tired after starting Успокой?

Regulatory documents classify drowsiness and dizziness as Common adverse effects of this medicine. This means that feeling tired or dizzy is frequently reported by users in clinical trials. Unexpected or severe tiredness should be noted in the context of the official safety profile.

Q: Are there any side effects that are considered rare for Успокой?

Yes, official product labeling for the active ingredients in Успокой does list adverse events categorized by how often they occur. This classification includes effects that are considered Rare or Very Rare, meaning they happen in a very small number of patients. These rarer events are tracked and reported in the official safety profile.

Q: Can Успокой affect blood pressure?

Generally, affecting blood pressure is not listed as a common side effect. However, regulatory information notes that low blood pressure (hypotension) has been reported as a potential effect, particularly in situations involving severe adverse reactions or an overdose.

Q: Is Успокой safe to use for a long period of time?

Regulatory guidelines strictly restrict the use of this medicine to short-term treatment only. Official labeling specifies that use should generally not exceed a period of four weeks, including any necessary gradual dose reduction. The medicine is indicated for the temporary support of sleep initiation.

Q: Is Успокой safe for people who have kidney issues?

Official product information indicates that for some active ingredients in this drug class, a specific dose adjustment may not be required for patients with kidney issues (renal impairment). However, regulatory guidance often describes the need for close monitoring for these patients during use.

Q: Can people with liver problems use Успокой?

Regulatory guidelines mandate that patients with liver issues (hepatic impairment) must start on a reduced initial dose. Furthermore, use of the medicine is generally not recommended or is contraindicated in individuals with severe forms of liver problems.

Q: Is Успокой approved for use in children?

Official regulatory documents state that this medicine is not recommended for use in children and adolescents under 18 years of age. This is because safety and efficacy have generally not been established for these age groups in clinical studies.

Q: What should I know about taking Успокой if I am pregnant?

Official information indicates that there are insufficient data available to definitively determine the drug-related risks for pregnant women. Therefore, the official recommendation is that the medicine should be used during pregnancy only if the potential benefits are considered to justify the risk to the fetus.

Q: Does the medicine come in different strengths or forms?

Yes, the active ingredients in this drug class are typically marketed in different strengths (for example, two common dosage strengths). Additionally, some active ingredients may be available in different formulations, such as immediate-release tablets and extended-release versions.

Q: Is it common for Успокой to cause strange dreams?

Official safety information for Успокой includes abnormal dreams as a documented adverse effect. This effect is typically categorized as Less Common, meaning it has been observed in clinical trials but does not occur as frequently as Common side effects like headache or dizziness.

Q: Are there any known severe allergic reactions to Успокой?

Yes, regulatory documents report instances of rare but serious allergic reactions associated with this class of medicine. These reactions include conditions like anaphylaxis and angioedema (swelling of the face or throat).

Q: Does Успокой have any restrictions regarding driving or operating machinery?

Official warnings strongly caution against activities that require full mental alertness after taking Успокой. This includes driving a car or operating machinery, as the medicine can cause next-day impairment, drowsiness, and affect coordination. These effects are detailed as potential risks that could affect safe functioning.

Q: Is there a generic version of Успокой available?

Since the active ingredients in Успокой belong to a well-established drug class, generic versions are widely available. These generic products are reviewed and approved by regulatory bodies to ensure they meet the same quality standards as the brand-name versions.

Q: Is Успокой a controlled substance?

Yes, the active ingredients in this medicine class are classified as controlled substances by governmental agencies (e.g., Schedule IV in the US). This classification is based on the drug's therapeutic use and its potential for dependence and misuse.

Q: What patient groups are generally advised not to use Успокой?

Official regulatory information states that the medicine is contraindicated, meaning it should not be used, in patients with specific severe conditions. These include severe breathing problems (respiratory insufficiency), severe liver problems (hepatic insufficiency), or documented sleep apnoea syndrome.

Q: Is the onset of action different between the tablet and capsule forms of Успокой?

When the medicine is available in both Immediate-Release (IR) and Extended-Release (ER) forms, the onset of action is different. The IR form is designed to work quickly to help with falling asleep, while the ER form may be designed to have a slower absorption to help with maintaining sleep.

Q: Are there any dietary restrictions I need to follow while using Успокой?

Official instructions caution against taking the medicine with or immediately after a heavy, high-fat meal. Doing so may significantly delay the absorption of the active ingredient, which could interfere with the expected rapid onset of the sleep effect.

Q: Does Успокой interact with grapefruit juice?

Yes, for certain active ingredients in this drug class, official documents include a warning regarding grapefruit juice. This is because grapefruit juice may interfere with the way the body catalyzes the medicine, potentially altering the drug's effects.

Q: Are there documented cases of overdose with Успокой?

Official regulatory labeling includes information detailing the management of an overdose with this class of medicine. This section describes potential symptoms such as changes in consciousness, profound drowsiness, and difficulty breathing.

Q: Do I need to inform my dentist about taking Успокой before a procedure?

Official patient counseling advice states the importance of informing all healthcare providers, including your dentist, that you are taking Успокой. This is important due to the risk of additive central nervous system (CNS) depressant effects, which is a concern if you receive anesthesia or other sedative medications during a procedure.

Q: How long do the effects of a single dose of Успокой last?

The sedative effect of a single dose is related to the drug's elimination half-life, which is the time it takes for half of the drug to be cleared from the body. This half-life is typically around 5 to 6 hours for the active ingredients in this class, influencing the duration of the effect.

Q: Does Успокой cause drowsiness during the day?

Official warnings highlight the risk of next-day impairment, which is a primary concern. This can manifest as daytime sleepiness, dizziness, or impaired coordination, even if you feel you have awakened completely. These effects can impact your ability to function safely.

Q: Is it required to take Успокой with food?

Official instructions generally recommend taking Успокой on an empty stomach or without food. This recommendation is based on the necessity for quick drug absorption to support the expected rapid onset of the sleep-inducing effect.

Q: Does Успокой interact with over-the-counter pain relievers?

A potential for additive central nervous system (CNS) depression exists when taken with over-the-counter pain relievers that contain other sedating ingredients. You should be aware of this risk if your pain reliever contains common sedating ingredients like certain antihistamines (e.g., diphenhydramine).

Q: Are there specific vitamins or supplements that interact with Успокой?

Yes, regulatory warnings exist for specific supplements and herbals. These include products known to cause sedation (such as kava or valerian) and those that are known to interfere with the liver enzyme systems that process the drug, like St. John's Wort.

Q: Has Успокой been studied in combination with other common mental health treatments?

Official drug interaction information notes the risk of additive sedation when Успокой is used alongside other medicines that slow brain activity, known as Central Nervous System (CNS) depressants. This drug class includes some commonly prescribed antidepressants and antipsychotics.

Q: Is the mechanism of action of Успокой fully understood?

The mechanism of action for this medicine is well-defined in official documents. It is understood to work by binding specifically to the GABA-A receptor complex, which helps enhance the effect of GABA (Gamma-aminobutyric acid), the brain’s natural calming agent, thereby reducing nerve activity.

Q: Can I take Успокой if I am already taking herbal sleep aids?

Regulatory information cautions that combining Успокой with herbal products known to cause sedation (such as valerian or kava) may lead to additive or potentiated sedative effects. This means the combined effects of the medications could be stronger than expected.

Q: Does Успокой affect sleep architecture (e.g., REM sleep)?

Clinical studies of this drug class often report that the medicine can affect sleep architecture, which refers to the stages of sleep. Official documentation indicates that the medicine may slightly increase the latency to REM sleep (the time before REM begins) or decrease REM density.

Q: Can Úспокой be taken with common cold and flu medications?

Caution is advised when taking Успокой with common cold and flu medications. Many of these preparations contain antihistamines or other ingredients that are classified as Central Nervous System (CNS) depressants, which could lead to dangerously high levels of additive sedation when combined with Успокой.

Storage and Disposal Requirements

Storage & Disposal Scope	Official Requirement
Labeled storage temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection requirements	Protect from moisture and excessive heat; keep the container tightly closed and in the original container.
Child-protection storage	Must be kept out of the sight and reach of children and secured in a safe place to prevent accidental ingestion or misuse.
Official disposal rules	Dispose of unused or expired medicine in accordance with local regulations; the preferred method is a drug take-back program or authorized collection site.
Environmental rules	The medicine must not be flushed down the toilet or poured into a drain unless it is specifically on the FDA's flush list.

The regulatory documents specify the exact temperature and environmental conditions required to preserve the product's stability. All unused tablets must be retained in the original packaging, and due to the nature of the medication, stringent child-safety storage practices are mandated. Disposal must follow official local procedures to avoid environmental contamination, prioritizing authorized collection methods.